These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia. Westermann J; Kopp J; van Lessen A; Hecker AC; Baskaynak G; le Coutre P; Döhner K; Döhner H; Dörken B; Pezzutto A Br J Haematol; 2007 May; 137(4):297-306. PubMed ID: 17408402 [TBL] [Abstract][Full Text] [Related]
24. Immunosuppressive properties of mesenchymal stem cells derived from bone marrow of patients with chronic myeloid leukemia. Zhao ZG; Li WM; Chen ZC; You Y; Zou P Immunol Invest; 2008; 37(7):726-39. PubMed ID: 18821219 [TBL] [Abstract][Full Text] [Related]
25. [Characteristics of the effect of myelosan on the immune status of patients with chronic myeloid leukemia]. Guseva SA Antibiot Khimioter; 1992 Aug; 37(8):46-8. PubMed ID: 1456828 [No Abstract] [Full Text] [Related]
26. Overexpression/enhanced kinase activity of BCR/ABL and altered expression of Notch1 induced acute leukemia in p210BCR/ABL transgenic mice. Mizuno T; Yamasaki N; Miyazaki K; Tazaki T; Koller R; Oda H; Honda ZI; Ochi M; Wolff L; Honda H Oncogene; 2008 May; 27(24):3465-74. PubMed ID: 18193087 [TBL] [Abstract][Full Text] [Related]
27. Is there an entity of chemically induced BCR-ABL-positive chronic myelogenous leukemia? Lichtman MA Oncologist; 2008 Jun; 13(6):645-54. PubMed ID: 18586919 [TBL] [Abstract][Full Text] [Related]
28. [Leucemogenesis of chronic myelogenous leukemia]. Mahon FX Rev Prat; 2005 Oct; 55(15):1642-6. PubMed ID: 16334200 [TBL] [Abstract][Full Text] [Related]
29. Chronic myeloid leukemia cells express tumor-associated antigens eliciting specific CD8+ T-cell responses and are lacking costimulatory molecules. Schmitt M; Li L; Giannopoulos K; Chen J; Brunner C; Barth T; Schmitt A; Wiesneth M; Döhner K; Döhner H; Greiner J Exp Hematol; 2006 Dec; 34(12):1709-19. PubMed ID: 17157168 [TBL] [Abstract][Full Text] [Related]
30. Biology of chronic myelogenous leukemia--signaling pathways of initiation and transformation. Melo JV; Deininger MW Hematol Oncol Clin North Am; 2004 Jun; 18(3):545-68, vii-viii. PubMed ID: 15271392 [TBL] [Abstract][Full Text] [Related]
31. Amplification of BCR-ABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia. Phan CL; Megat Baharuddin PJ; Chin LP; Zakaria Z; Yegappan S; Sathar J; Tan SM; Purushothaman V; Chang KM Cancer Genet Cytogenet; 2008 Jan; 180(1):60-4. PubMed ID: 18068536 [TBL] [Abstract][Full Text] [Related]
32. Evidence that a BCR-ABL fusion peptide does not induce lymphocyte proliferation or cytokine production in vitro. Abu-Eisha HM; Butt NM; Clark RE; Christmas SE Leuk Res; 2007 Dec; 31(12):1675-81. PubMed ID: 17324459 [TBL] [Abstract][Full Text] [Related]
33. Out of frame peptides from BCR/ABL alternative splicing are immunogenic in HLA A2.1 transgenic mice. Casnici C; Volpe G; Lattuada D; Crotta K; Kuka M; Panuzzo C; Mastrotto C; Tonon G; Fazio VM; Saglio G; Marelli O Cancer Lett; 2009 Apr; 276(1):61-7. PubMed ID: 19062160 [TBL] [Abstract][Full Text] [Related]
34. [Kinetics of proliferation, differentiation and transcription of genes regulating apoptosis in cultured human BCR/ABL+ Ph+-cells]. Akhlynina TV; Gerasimova LP; Sarkisian GP; Borovkova TV; Dukhovenskaia EA; Manakova TE; Naĭdenova NM; Timofeev AM; Grineva NI Tsitologiia; 2007; 49(10):889-900. PubMed ID: 18074781 [TBL] [Abstract][Full Text] [Related]
35. CD8+ memory T cells predominate over naïve T cells in therapy-free CML patients with sustained major molecular response. Usuki K; Yokoyama K; Nagamura-Inoue T; Ito A; Kida M; Izutsu K; Urabe A; Tojo A Leuk Res; 2009 Sep; 33(9):e164-5. PubMed ID: 19371950 [No Abstract] [Full Text] [Related]
36. Clinical grade expansion of CD45RA, CD45RO, and CD62L-positive T-cell lines from HLA-compatible donors: high cytotoxic potential against AML and ALL cells. Barbui AM; Borleri G; Conti E; Ciocca A; Salvi A; Micò C; Introna M; Rambaldi A Exp Hematol; 2006 Apr; 34(4):475-85. PubMed ID: 16569594 [TBL] [Abstract][Full Text] [Related]
38. Altered IFNgamma signaling and preserved susceptibility to activated natural killer cell-mediated lysis of BCR/ABL targets. Cebo C; Voutsadakis IA; Da Rocha S; Bourhis JH; Jalil A; Azzarone B; Turhan AG; Chelbi-Alix M; Chouaib S; Caignard A Cancer Res; 2005 Apr; 65(7):2914-20. PubMed ID: 15805294 [TBL] [Abstract][Full Text] [Related]
39. Expansion and activation of minor histocompatibility antigen HY-specific T cells associated with graft-versus-leukemia response. Takami A; Sugimori C; Feng X; Yachie A; Kondo Y; Nishimura R; Kuzushima K; Kotani T; Asakura H; Shiobara S; Nakao S Bone Marrow Transplant; 2004 Oct; 34(8):703-9. PubMed ID: 15322566 [TBL] [Abstract][Full Text] [Related]
40. Association of HLA Class I and Class II genes with bcr-abl transcripts in leukemia patients with t(9;22) (q34;q11). Mundhada S; Luthra R; Cano P BMC Cancer; 2004 Jun; 4():25. PubMed ID: 15202948 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]